dc.contributor.author | Keane, Colm | |
dc.contributor.author | Nourse, Jamie P. | |
dc.contributor.author | Crooks, Pauline | |
dc.contributor.author | Nguyen-Van, Do | |
dc.contributor.author | Mutsando, Howard | |
dc.contributor.author | Mollee, Peter | |
dc.contributor.author | Lea, Rodney | |
dc.contributor.author | Gandhi, Maher K. | |
dc.date.accessioned | 2018-01-25T12:30:34Z | |
dc.date.available | 2018-01-25T12:30:34Z | |
dc.date.issued | 2012 | |
dc.date.modified | 2013-05-24T02:37:27Z | |
dc.identifier.issn | 14440903 | |
dc.identifier.doi | 10.1111/j.1445-5994.2011.02587.x | |
dc.identifier.uri | http://hdl.handle.net/10072/50781 | |
dc.description.abstract | Background Recent reports suggest genetic polymorphisms influence susceptibility to rituximab induced late-onset neutropenia (LON), which in turn may be a predictor of good outcome in B-cell lymphoma. Aims We report the largest study to date assessing FCGR3A-V158F polymorphisms in Diffuse Large B-cell Lymphoma (DLBCL) treated with CHOP-R. The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. Methods 115 DLBCL patients treated with CHOP-R were compared with 105 healthy Caucasian controls with regards to FCGR3A-V158F and C1qA-A276G polymorphisms . LON incidence and event free and overall survival (EFS and OS) were analysed for linkage to either polymorphism. Results The FCGR3A-V158F but not the C1qA-A276G polymorphism influenced the risk of developing LON. 50% of FCGR3A-158V/V patients experienced LON. In contrast, only 7% V/F and 2% F/F experienced LON. The FCGR3A-158V/V genotype was associated with LON compared to V/F (p=0.028) and F/F genotypes (p=0.005). Although no patients with either LON or FCGR3A-158V homozygosity relapsed compared to 33% FCGR3A-158F/F and 21% non-LON, this did not translate into improved EFS or OS. Conclusions Polymorphic analysis may be a predictive tool to identify those at high-risk of LON. Prospective studies are required to definitively establish if LON or FCGR3A-158V/V genotype influences outcome. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.publisher | Wiley-Blackwell Publishing Asia | |
dc.publisher.place | Australia | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 1113 | |
dc.relation.ispartofpageto | 1119 | |
dc.relation.ispartofissue | 10 | |
dc.relation.ispartofjournal | Internal Medicine Journal | |
dc.relation.ispartofvolume | 42 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Immunogenetics (incl. Genetic Immunology) | |
dc.subject.fieldofresearch | Cardiorespiratory Medicine and Haematology | |
dc.subject.fieldofresearch | Clinical Sciences | |
dc.subject.fieldofresearch | Public Health and Health Services | |
dc.subject.fieldofresearchcode | 110706 | |
dc.subject.fieldofresearchcode | 1102 | |
dc.subject.fieldofresearchcode | 1103 | |
dc.subject.fieldofresearchcode | 1117 | |
dc.title | Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for Diffuse Large B-cell Lymphoma | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
dc.description.version | Accepted Manuscript (AM) | |
gro.rights.copyright | © 2012 Royal Australasian College of Physicians. This is the peer reviewed version of the following article: Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma, Internal Medicine Journal, Volume 42, Issue 10, Pages 1113–1119, which has been published in final form at 10.1111/j.1445-5994.2011.02587.x. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html) | |
gro.date.issued | 2012 | |
gro.hasfulltext | Full Text | |
gro.griffith.author | Lea, Rodney A. | |